Risk of primary and recurrent acute myocardial infarction from lipoprotein(a) in men and women

Journal of the American College of Cardiology

Volumn 28, Issue 4, 1996, Pages 870-875

  Kinlay, Scott ^b   Dobson, Annette J ^c   Heller, Richard F ^c   McElduff, Patrick ^c   Alexander, Hilary ^c   Dickeson, John ^a  

^a JOHN HUNTER HOSPITAL   (Australia)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN A;

ACUTE HEART INFARCTION; ADULT; ARTICLE; AUSTRALIA; BLOOD VESSEL INJURY; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT;

EID: 0347865105     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(96)00238-0     Document Type: Article

References (25)

1. Utermann G. The mysteries of lipoprotein(a). Science 1989;246:904-10.
2. Miles LA, Fless GM, Levin EG, Scanu AM. Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989;339:301-3.
3. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303-5.
4. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990;10:240-5.
5. Schaefer EJ, Lamon-Fava S, Jenner JLet al. Lipoprotein(a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention trial. JAMA. 271:1994;999-1003.
6. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ 1990;301:1248-51.
7. Kark JD, Sanholzer C, Friedlander Y, Utermann G. Plasma lipoprotein(a), apolipoprotein(a) isoforms and acute myocardial infarction in men and women: a case-control study in the Jerusalem population. Atherosclerosis 1993;98:139-51.
8. Dahlen GH, Guyton JR, Altar M, Farmer JA, Kautz JA, Gotto AM. Association of levels of lipoprotein(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986;74:758-65.
9. Simons L, Friedlander Y, Simons J, McCallum J Lipoprotein(a) is not associated with coronary heart disease in the elderly: cross-sectional data from the Dubbo Study. Atherosclerosis. 99:1993;87-95.
10. Jauhiainen M, Koskinen P, Ehnholm Cet al. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 89:1991;59-67.
11. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993;270:2195-9.
12. Alfthan G, Pekkanen J, Jauhiainen Met al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population-based study. Atherosclerosis. 106:1994;9-19.
13. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A Myocardial infarction and coronary deaths in the World Health Organisation MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 90:1994;583-612.
14. Mbewu AD, Durrington PN, Bulleid S, Mackness MI The immediate effect of streptokinase on serum lipoprotein(a) concentrations and the effect of myocardial infarction on serum lipoprotein(a), apolipoproteins A1 and B, lipids and C-reactive protein. Atherosclerosis. 103:1993;65-71.
15. Kinlay S, Dobson AJ, Heller RF, Dickeson JE, Ryan S. Lipid and apolipoprotein levels in an Australian community. Med J Aust 1991;154:170-5.
16. Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels: the Framingham Offspring Study. Circulation 1993;87:1135-41.
17. Cobbaert C, Kesteloot H. Serum lipoprotein(a) levels in racially different populations. Am J Epidemiol 1992;136:441-9.
18. Genest J Jr, Jenner JL, McNamara JR, et al. Prevalence of lipoprotein(a) [Lp(a)] excess in coronary artery disease. Am J Cardiol 1991;67:1039-45.
19. Wang XL, Tam C, McCredie RM, Wilcken DEL. Determinants of severity of coronary artery disease in Australian men and women. Circulation 1994;89:1974-81.
20. Parlavecchia M, Pancaldi A, Taramelli R, et al. Evidence that apolipoprotein(a) phenotype is a risk factor for coronary artery disease in men <55 years of age. Am J Cardiol 1994;74:346-51.
21. Marburger C, Hambrecht R, Neibauer J, et al. Association between lipoprotein(a) and progression of coronary artery disease in middle-aged men. Am J Cardiol 1994;73:742-6.
22. Terres W, Tatsis E, Pfalzer B, Beil U, Beisiegel U, Hamm CW. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation 1995;91:948-50.
23. Utermann G, Kraft HG, Menzel HJ, Hopferwieser T, Seitz C. Genetics of the quantitative Lp(a) lipoprotein trait. I. Relation of Lp(a) glycoprotein phenotypes to Lp(a) lipoprotein concentrations in plasma. Hum Genet 1988;78:41-6.
24. Sandholzer C, Saha N, Kark JK, et al. Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arteriosclerosis Thromb 1992;12:1214-26.
25. Marconvina SM, Albers JJ, Jacobs DR, et al. Lipoprotein[a] concentrations and apolipoprotein(a) phenotypes in Caucasians and African Americans: the CARDIA study. Arteriosclerosis Thromb 1993;13:1037-45.